SLFN11 expression increases the sensitivity of prostate cancer cells to platinum-based drugs in vitro, and knockout of SLFN11 in human prostate cancer organoids increases the resistance to Cisplatin and Olaparib (Poly (ADP-ribose) polymerase inhibitors, PARPi) in prostatic organoids [69]. This evidence concerns the gene SLFN11 and prostate cancer.